Εμβριθής έρευνα και οδηγοί ειδικών για τη διατήρηση της οπτικής σας υγείας.
Παρακάτω εξηγούμε πώς λειτουργούν αυτές οι νέες θεραπείες, ποιοι μπορεί να ωφεληθούν και πώς συγκρίνονται με τα παραδοσιακά κολλύρια. Εστιάζουμε στις...
Τα τυφλά σημεία αναπτύσσονται συχνά σταδιακά χωρίς συμπτώματα. Ξεκινήστε μια δωρεάν δοκιμή και κάντε μια γρήγορη δοκιμή οπτικού πεδίου για να εντοπίσετε έγκαιρα τις αλλαγές.
Μάθετε ΤώραiDose TR is a tiny implantable device designed to deliver the glaucoma medicine travoprost directly inside the eye over an extended period. A doctor places it in a small procedure so the device sits where the drug can reach the tissues that control fluid pressure. Instead of applying eye drops every day, the device releases medication slowly and continuously, aiming to keep eye pressure stable. This steadier dosing can reduce the burden of daily treatment and help people who have trouble using drops correctly. Some versions of the device are designed so a clinician can remove or replace them if needed, giving flexibility in long-term management. As with any implant, there are risks such as procedure-related infection, device movement, or local tissue reactions that doctors watch for. Not every patient is a candidate, and the choice between an implanted system and traditional drops depends on eye anatomy, disease severity, and personal preference. iDose TR matters because it represents a shift toward treating chronic eye conditions with steady, low-maintenance approaches that may improve outcomes. Patients considering it should discuss expected benefits, possible complications, and follow-up care with their eye specialist before deciding so they understand how it fits into their plan to keep vision healthy.
